Liquid biopsy biomarker identifies patients with improved response to PARP inhibition in metastatic castrate resistant prostate cancer.
Epic Sciences announced findings demonstrating a circulating tumor cell (CTC) biomarker can identify patients with metastatic castrate resistant prostate cancer (mCRPC) who are more likely to respond to treatment with a PARP inhibitor in combination with androgen receptor signaling inhibitors (ARSi) compared to those treated with ARSi alone (overall response rate of 93 percent vs. 22 percent).
Epic Sciences validates single CTC sequencing, identifies clonal heterogeneity in metastatic cancer.
Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells (CTC) and demonstrated clinical feasibility in metastatic prostate cancer patients (mCRPC).
Epic Sciences to present at the Canaccord Genuity Medical Technology & Diagnostics Forum.
Epic Sciences, Inc. a private biotech company that designs and develops predictive tests of therapy response in cancer, announced today that Murali K. Prahalad, Ph.D., chief executive officer, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 17, 2016 at 10:20 a.m. EST. The conference will be held at the Westin Grand Central in New York.
Epic Sciences to contribute to Cancer Moonshot Blood Profiling Atlas.
Epic Sciences will contribute to the Blood Profiling Atlas pilot of the Cancer Moonshot Initiative championed by Vice President Biden and the White House. The Blood Profiling Atlas seeks to create an open database of results from liquid biopsy tests to accelerate the development of safe and effective blood profiling diagnostics for patient benefit.
Genomic Health and Epic Sciences announce strategic collaboration to deliver novel AR-V7 liquid biopsy test.
Genomic Health, Inc. and Epic Sciences, Inc. today announced an exclusive agreement to commercialize Epic Sciences’ novel AR-V7 liquid biopsy test in the United States through Genomic Health’s world-class commercial channel.
Epic Sciences introduces sensitive HRD liquid biopsy test for PARP inhibitor clinical trials.
Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency (HRD) in individual circulating tumor cells (CTCs).
Presence of AR-V7 in circulating tumor cells validated as predictive biomarker for advanced prostate cancer treatment by Memorial Sloan Kettering and Epic Sciences.
New Publication: JAMA Oncology 2016.